Evidence map›Paper›PMID 30444997›Full record

ArticleMolecular cell2018

If You'd Like to Stop a Type III CRISPR Ribonuclease, Then You Should Put a Ring (Nuclease) on It.

Charlie Y Mo, Luciano A Marraffini

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Molecular cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Charlie Y MoLaboratory of Bacteriology, The Rockefeller University, New York, NY 10065, USA.
Luciano A MarraffiniLaboratory of Bacteriology, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA. Electronic address: marraffini@mail.rockefeller.edu.
Howard Hughes Medical Institute · USRockefeller University · US

Funding

Generation of immunological memory by CRISPR-Cas systemsDP1GM128184 · NIGMS · ROCKEFELLER UNIVERSITY · PI MARRAFFINI, LUCIANO A · 2017 to 2021
$5.9M
Biochemical and cellular DNA targeting by the type III-A CRISPR-Cas systemF32GM128271 · NIGMS · ROCKEFELLER UNIVERSITY · PI MO, CHARLIE YE · 2018 to 2019
$120k
Biotechnology and Biological Sciences Research Council BB/M000400/1Biotechnology and Biological Sciences Research Council BB/M021017/1Howard Hughes Medical InstituteNIGMS NIH HHS DP1 GM128184NIGMS NIH HHS F32 GM128271
6 · The paper itself

Abstract

Athukoralage et al. (2018) identify a new class of nuclease that degrades cyclic oligoadenylate (cOA), a second messenger that activates non-specific RNA degradation by the type III CRISPR-Cas accessory RNase Csm6/Csx1. This discovery provides a mechanism for regulating the degradation of foreign transcripts during the type III CRISPR immune response.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsRibonucleasesAdenine NucleotidesCRISPR-Cas SystemsOligoribonucleotides2',5'-oligoadenylateAdenine NucleotidesOligoribonucleotidesRibonucleases

Identifiers

PMID30444997
OpenAlexW2901081344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.